Who we are
BiVictriX is a rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies.
We have developed Bi-Cygni® therapeutics, which are uniquely selective for particular cancer types, to enable higher dosing and more aggressive cancer eradication without causing harmful side effects.
We apply state of the art techniques to identify combinations of cancer-specific targets for both solid and liquid tumours.
Our novel approach to cancer therapy
Selectivity
By selectively identifying cancer cells, we can avoid hitting vital healthy cells with anti-cancer treatments.
High potency
This enables a much higher dose of treatment to be safely given to the patient to effectively kill the cancer cells.
More effective
Enabling more effective anti-cancer treatment without causing harmful side-effects.
Bi-Cygni® therapeutics make this possible
BiVictriX team
Leadership and Advisory Team
Tiffany Thorn
Founder & Chief Executive Officer
View Profile
Tiffany Thorn
Founder & Chief Executive Officer
- Experienced ADC executive with a sixteen-year career in healthcare spanning the biotech and clinical setting
- Founder of BiVictriX and pioneer of the bsADC approach
- Qualified Clinical immunologist, with experience in frontline clinical care
- Co-Chair of the UK Sepsis Trust
Michael Kauffman, M.D., Ph.D
Non-Executive Chairman
View Profile
Michael Kauffman, M.D., Ph.D
Non-Executive Chairman
- Seasoned life sciences executive with >25 years of experience spanning preclinical research, clinical development & regulatory strategy.
- Co-Founder & Former CEO of Karyopharm, securing >$1bn in investment
- Former CMO of Onyx & Proteolix
- Three successful drug approvals (Xpovio®, Kyprolis® & Velcade®)
Petter Veiby, Ph.D
Non-Executive Director
View Profile
Petter Veiby, Ph.D
Non-Executive Director
- Experienced life sciences executive and seasoned ADC developer with >25 years of experience spanning preclinical and clinical development across biotech & pharma
- Co-Founder & CSO at ATTOVIA, securing >$250m since 2023
- Former Head of Alliances and BD Search and Evaluation at Zai Lab
- 20+ years in leadership positions within Oncology Drug Discovery Unit at Millennium/Takeda
Richard Sainson Ph.D
Senior Scientific Advisor
View Profile
Richard Sainson Ph.D
Senior Scientific Advisor
- Seasoned life sciences executive/CSO with deep expertise across biotech & pharma and end-to-end experience from target validation to Phase II PoC
- Led >15+ preclinical programs and Contributed to 7 CTA/IND submissions and phase I/II trials (Biologics, Antibodies, Bispecifics & ADCs)
- Strong relationships with key institutions, KOLs, pharma partners and investors
- Significant expertise in partnering and strategic collaborations
Chris Primiano
Chief Business Officer
View Profile
Chris Primiano
Chief Business Officer
- Experienced business and legal professional with a twenty-year career working with biotechnology and other life sciences companies
- Former CBO of Aura
- Former CBO & General Counsel of Karyopharm
- Former corporate and life sciences attorney at WilmerHale
